文献速递肝胆胰外科围术期管理与 ERAS

自体输血对结直肠癌肝转移部分肝切除患者生存与复发的影响

Impact of Autologous Blood Transfusion on Survival and Recurrence among Patients Undergoing Partial Hepatectomy for Colorectal Cancer Liver Metastases.
PubMed 文献 · J Am Coll Surg · 2018-11-16

中位随访54个月,两组中位总生存期分别为59个月与54个月(p=0.69),无复发生存率分别为27%与37%(p=0.22),调整后风险比均无统计学差异。结论认为自体输血不增加复发风险或死亡率。

要点

  • 自体输血组与未输血组总生存期和无复发生存率均无显著差异。
  • 调整混杂因素后,自体输血与复发风险及死亡风险无显著关联。
  • 对结直肠癌肝转移行肝切除患者,可安全输注滤过的自体血。

核心结论

  • 自体输血与结直肠癌肝转移部分肝切除患者复发风险增加或死亡率升高无关。
  • 肝切除 surgeons 可安全输注滤过的自体血。

研究设计与样本

  • 单中心回顾性分析,纳入147例因结直肠癌肝转移行部分肝切除术的患者。

主要发现

  • 自体输血组失血量更大、切除范围更广、手术时间更长。
  • 两组年龄、性别、结肠与直肠癌比例、Fong临床风险评分无差异。
  • 中位随访54个月,自体输血组中位总生存期59个月,未输血组54个月(p=0.69)。
  • 调整年龄、性别、Fong评分、癌症类型、新辅助/辅助治疗、切除范围和失血量后,总生存风险比0.58(95%CI 0.31-1.11;p=0.10)。
  • 无复发生存率自体输血组27% vs 未输血组37%(p=0.22),调整风险比0.95(95%CI 0.54-1.65;p=0.85)。

临床怎么用

  • 对结直肠癌肝转移行部分肝切除术的患者,可安全使用滤过的自体血输血。
  • 自体输血不增加肿瘤复发或死亡风险,不应因理论风险而避免使用。

局限性

  • 回顾性单中心设计,样本量有限(147例),可能存在选择偏倚。
  • 自体输血组失血量更大、切除范围更广、手术时间更长,提示基线风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autologous transfusion (AT) has long been considered unsafe in major oncologic operations due to a theoretic risk of spreading metastatic disease, however, few data support this assumption. STUDY DESIGN: We conducted a retrospective analysis of 147 patients who underwent partial hepatectomy for colorectal cancer metastases at a single institution. Seventy-four patients received AT only and 73 received no transfusion (NT). We compared the overall survival and recurrence-free survival of these groups using Kaplan-Meier survival curves and adjusted hazard ratios. RESULTS: Patients who received AT had greater blood loss, more extensive resections, and longer procedure times. There were no differences in age, sex, proportion colon vs rectal cancer, or Fong Clinical Risk Score. Mean follow-up was 54 months. Median overall survival in the AT group was 59 months compared with 54 months in the NT group (p = 0.69) on log-rank test. No difference in overall survival was noted after adjusting for age, sex, Fong score, type of cancer (colon vs rectal), receipt of neoadjuvant therapy, receipt of adjuvant therapy, extent of resection and blood loss (hazard ratio AT vs NT 0.58; 95% CI 0.31 to 1.11; p = 0.10). Recurrence-free survival was also similar in the AT and NT groups (27% vs 37%; p = 0.22). The adjusted hazard ratio for recurrence-free survival was 0.95 (95% CI 0.54 to 1.65; p = 0.85). CONCLUSIONS: Autologous blood transfusion is not associated with an increased recurrence risk or a higher mortality rate. Surgeons performing liver resections for patients with colorectal cancer metastases can safely transfuse filtered autologous blood.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Kang R, Seath BE, Huang V, et al. Impact of Autologous Blood Transfusion on Survival and Recurrence among Patients Undergoing Partial Hepatectomy for Colorectal Cancer Liver Metastases. J Am Coll Surg. 2018. PMID: 30448300. doi:10.1016/j.jamcollsurg.2018.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。